Education
About Us
Working with TipRanks
Follow Us
InspireMD (NSPR)
NASDAQ:NSPR
NSPR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.99 - $3.80
Previous CloseN/A
Volume8.46K
Average Volume (3M)289.18K
Market Cap
$85.47M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Aug 05, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding30,635,345
10 Day Avg. Volume123,959
30 Day Avg. Volume289,184
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.50Price Target Upside67.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialInspireMD could be an attractive add-on for Boston or other big MedTech cardiovascular players.
Analyst RecommendationAnalyst recommends a Buy rating and a $5 price target.
Business GrowthInspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.
Market ShareBest-in-class data should result in fast share taking for InspireMD's CGuard.
Product PerformanceThe 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%, supporting a quick share shift within the TF-CAS market.
Regulatory ApprovalInspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.
Bears Say
InspireMD News
NSPR FAQ
What was InspireMD’s price range in the past 12 months?
InspireMD lowest stock price was $1.99 and its highest was $3.80 in the past 12 months.
What is InspireMD’s market cap?
InspireMD’s market cap is $85.47M.
When is InspireMD’s upcoming earnings report date?
InspireMD’s upcoming earnings report date is Aug 05, 2025 which is in 3 days.
How were InspireMD’s earnings last quarter?
InspireMD released its earnings results on May 09, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.02.
Is InspireMD overvalued?
According to Wall Street analysts InspireMD’s price is currently Undervalued.
Does InspireMD pay dividends?
InspireMD does not currently pay dividends.
What is InspireMD’s EPS estimate?
InspireMD’s EPS estimate is -0.26.
How many shares outstanding does InspireMD have?
InspireMD has 30,635,345 shares outstanding.
What happened to InspireMD’s price movement after its last earnings report?
InspireMD reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InspireMD?
Currently, no hedge funds are holding shares in NSPR
InspireMD Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (67.29% Upside)
$4.50 (67.29% Upside)
Insider Transactions
Bought Shares
Worth $539.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.12%
12-Months-Change
Fundamentals
Return on Equity
-113.95%
Trailing 12-Months
Asset Growth
-7.99%
Trailing 12-Months
Company Description
InspireMD
InspireMD, Inc. (NSPR) is a medical device company focused on the development and commercialization of its proprietary MicroNet™ technology for the treatment of complex vascular and coronary artery diseases. The company's flagship product is the CGuard™ Embolic Prevention System (EPS), which is designed to prevent embolization in carotid artery stenting procedures. InspireMD operates primarily in the cardiovascular sector, offering innovative solutions aimed at improving patient outcomes in the treatment of vascular diseases.
NSPR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a mix of positive developments and challenges. While there was growth in CGuard revenue and significant progress in clinical trials and commercial preparations, the company faced increased operating expenses and a higher net loss. The anticipated delay in FDA approval also presents a challenge. However, the potential U.S. market opportunity and strategic progress provide optimism.Read More>NSPR Stock 12 Month Forecast
Average Price Target
$4.50
▲(67.29%Upside)
Technical Analysis
Ownership Overview
24.99% Insiders
0.06% Mutual Funds
0.73% Other Institutional Investors
74.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---